Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Weston

Cardiovascular Disease Bradenton, FL Medical Doctor

NPI 1306813423 CMS profile 940294

300 Riverside Dr E Ste 2010, Bradenton, FL 34208

Open in the dashboard

General payments

$3,932

29 records reported · program years 2019–2025

Research payments

$58,423

Paid to them · 32 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,222,495 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patrick Weston of Bradenton, FL is reported in the CMS Open Payments database as having received $3,932 across 29 general payments and $58,423 in research payments paid to them. Separately, studies naming them as principal investigator received $1,222,495 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $916 6
2024 General $3,542 14
2023 General $12 1
2022 Research $4,000 5
2021 General $38 2
2021 Research $33,402 8
2020 General $50 3
2020 Research $10,305 7
2019 General $290 9
2019 Research $9,800 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Weston
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Patrick Weston were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Patrick Weston Cardiovascular Disease median Middle half National median
2019 $290 $450 $127–$1,392 $163
2020 $50 $242 $77–$751 $114
2021 $38 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $12 $443 $136–$1,283 $160
2024 $3,542 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,253 11 payments
  2. Echosens North America, Inc. $1,200 2 payments
  3. Biosense Webster, Inc. $99 1 payment
  4. Gilead Sciences, Inc. $89 1 payment
  5. United Therapeutics Corporation $77 1 payment
  6. Amarin Pharma Inc. $45 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $38 2 payments
  8. AstraZeneca Pharmaceuticals LP $31 2 payments
  9. Actelion Pharmaceuticals US, Inc. $26 2 payments
  10. Medtronic Vascular, Inc. $20 1 payment
  11. Other $55 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,122 6 payments
  2. Consulting Fee $1,200 2 payments
  3. Food and Beverage $572 19 payments
  4. Education $38 2 payments
Products named General payments · program years 2019–2025
  1. FibroScan $1,200 2 payments
  2. Carto 3 System $99 1 payment
  3. ORENITRAM $77 1 payment
  4. TYVASO $77 1 payment
  5. REMODULIN $77 1 payment
  6. Vascepa $45 2 payments
  7. JARDIANCE $38 2 payments
  8. OPSUMIT $26 2 payments
  9. Azure $20 1 payment
  10. BRILINTA $16 1 payment
  11. Other $70 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $23,630 4 payments
  2. Vifor (International) Ltd. $19,600 12 payments
  3. First Wave BioPharma, Inc. $14,277 10 payments
  4. GlaxoSmithKline, LLC. $916 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Cardiology: 2,533

Drug cost

$811

Median for Cardiology: $485,213

Branded share of claims

0%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pindolol Generic 11 $811

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record